Title: J&J Boosts Outlook Despite Incoming Tariff Costs
Date: 2025-04-15 15:04
URL: https://finance.yahoo.com/m/7587a6b8-41b1-38a1-b035-d05170727a2f/j%26j-boosts-outlook-despite.html?.tsrc=rss
Content:
Oops, something went wrong Tip: Try a valid symbol or a specific company name for relevant results Oops, something went wrong The chip giant committed to building AI infrastructure in the US, and Trump says he's going to help make it happen. The fallout from Trump's tariff whiplash hasn't yet pushed investors to shy away from an old habit Stocks edge higher after back-to-back rallies with Trump's latest tariff moves in focus BofA's Moynihan says 'we potentially face a changing economy' after highest-ever equities trading haul The trade war uncovers new economies of scale Trump is wrecking his own economic agenda Higher clothing costs from tariffs are coming soon — but not immediately, experts say Why Tesla, GM, and Rivian will be hurt most by China's critical minerals export ban Trump says he's 'looking at something' to help car companies with tariffs Stocks rally for second straight day, while Apple jumps on tech tariff reprieve The Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon trading Americans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey found Stocks surge as Apple leads way higher after tech's tariff reprieve Trump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bend Goldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slows Corporate earnings take center stage amid tariff turmoil: What to know this week Trump has tariffs, taxes, and the debt ceiling on a collision course for this summer Trump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg) Tax day 2025 is coming up. Here’s what to know to file by the deadline. Commentary: Put the P/E ratio in timeout for now Market chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landing Apple was on brink of crisis before tariff concession from Trump (Bloomberg) Corporate earnings take center stage amid tariff turmoil: What to know this week The best (and worst) time of year to buy a house The Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg) How to invest in gold in 4 steps Changing jobs can disrupt saving for retirement. Here's how to stay on track. Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg) Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard of The tariff uncertainty isn't getting any better in markets: Chart of the Week 'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflation Gold notches best week since 2020 amid 'shaken' investor confidence in US The bond market just had one of its most volatile and unusual weeks in recent memory Stocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023 Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains. The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market. Consumer sentiment craters further as inflation expectations soar to highest since 1981 Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll in JPMorgan's Dimon says economy is facing 'considerable turbulence' Tariff uncertainty muddies — and refocuses — earnings season China raises tariffs on US goods to 125% from the 84% planned in response to Trump's latest hike China already knows Trump's breaking point in their burgeoning trade war, our columnist writes How the bond market helped make Trump blink on tariffs The Dow fell 1,000 points, and the S&P 500 and Nasdaq were crushed as stocks resumed a tariff-fueled sell-off Trump's total tariff on China is actually 145%, the White House said, an amount higher than the 125% previously reported Stocks hit session lows as focus turned to the US-China trade war. The Dow lost over 1,200 points, and the Nasdaq plunged 4.5%. The Dow plummeted 900 points and the Nasdaq plunged over 3% as a tariff-fueled sell-off picked up speed again. Stocks plummet as Wall Street's euphoria from Trump's tariff pause gets a reality check Inflation unexpectedly tumbled in March, and core CPI rose at its slowest pace in four years. The EU matched Trump's 90-day pause on tariffs to 'give negtiations a chance.' See our live updates. Unlock stock picks and a broker-level newsfeed that powers Wall Street. New tariffs, primarily on medical technology products, are projected to add $400 million in costs this year, Chief Financial Officer Joseph Wolk said. J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition. Johnson & Johnson stock slipped on Tuesday, even after the company reported first-quarter earnings that surpassed expectations, and boosted its full-year sales forecast. The company said it now expects operational sales of $92 billion, versus a prior forecast of $91.3 billion. J&J also guided for estimated reported sales of $91.4 billion, up from a previous $89.6 billion. Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt primarily within the company's medical technology unit, which makes a range of medical devices and surgical products. The most substantial impact comes from tariffs against China and retaliatory tariffs from China, said Joseph Wolk, Johnson & Johnson's chief financial officer, in a conference call with analysts following the company's latest earnings results. J&J faces several headwinds at the start of the year, including patent expiry, talc litigation, and, now, tariffs. Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would conduct an investigation into drug imports. That move is widely seen as a first step toward imposing new levies. Earnings and revenue both beat estimates for the quarter. Johnson & Johnson CFO Joe Wolk joined Bloomberg Open Interest to talk about how tariffs could hit the industry and the drug maker's bottom line. The average brokerage recommendation (ABR) for Cisco (CSCO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock? C's first-quarter 2025 results benefit from a rise in NII and a fall in expenses. Rising loans and deposits balance acts as another positive. The streamer’s shares have climbed 51% over the past year, powered higher by a password-sharing crackdown and a new ads business. Johnson & Johnson stock fell alongside the broader market, despite beating first-quarter calls and hiking its 2025 sales guidance. Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 7.78% and 1.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock? Tip: Try a valid symbol or a specific company name for relevant results Sign in to access your portfolio Try again.
